



## CLARITI STUDY FEATURED IN BEST OF DIGESTIVE DISEASE WEEK

**Immunovia's (IMMNOV: Nasdaq Stockholm) CLARITI study was presented in a distinguished plenary session at Digestive Disease Week (DDW) 2025 and was further recognized in the conference's closing session, Best of DDW.**

The selection highlights the study's exceptional scientific and clinical significance and places it among the most impactful research presented at the world's largest conference in gastroenterology.

"This recognition reinforces the strength of our clinical validation study and the opportunity our test represents in addressing a critical unmet need," said Dr. Norma Palma, Vice President of Clinical and Medical Affairs at Immunovia and co-author of the study.

Dr. Aimee Lee Lucas, Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai Morningside Hospitals and a member of Immunovia's Scientific Advisory Board, presented the study findings. The CLARITI study demonstrated strong performance of Immunovia's novel blood-based biomarker test for early detection of pancreatic cancer in a high-risk population.

Digestive Disease Week brings together more than 13,000 global attendees, including clinicians, researchers, and decision-makers. Recognition in both the plenary and Best of DDW sessions underscores Immunovia's growing leadership in early cancer detection and the potential impact of its technology in clinical practice.

**For further information, please contact**

Jeff Borcharding, CEO

[jeff.borcharding@immunovia.com](mailto:jeff.borcharding@immunovia.com)

**Immunovia in brief**

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.  
For more information, please visit [www.immunovia.com](http://www.immunovia.com).